Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2019-03-21 Capital/Financing Update
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent offentliggör prospekt avseende företrädesemission och riktad emission
Capital/Financing Update Classification · 98% confidence The document is a press release dated March 21, 2019, announcing that the prospectus for a rights issue (företrädesemission) and a directed issue (riktad emission) has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) and is now available. The text explicitly states that the invitation to subscribe will only be made through the prospectus. This structure—a short announcement stating that a formal offering document (prospectus) is now available—fits the definition of a Report Publication Announcement (RPA), as it is announcing the publication of a key financial/capital document rather than being the full prospectus or a general regulatory filing (RNS). It is not a 10-K, IR, or ER, but specifically announces the availability of offering documents related to capital raising.
2019-03-21 Swedish
BioInvent publishes prospectus relating to the rights issue and directed issue
Capital/Financing Update Classification · 95% confidence The document is a press release dated March 21, 2019, titled "BioInvent publishes prospectus relating to the rights issue and directed issue." It explicitly states that the prospectus has been approved and registered and is now available on several websites. This document is an announcement about the publication of a prospectus related to a financing activity (rights issue and directed issue). This fits the definition of a Capital/Financing Update (CAP) as it details fundraising activities. However, since the document itself is an announcement *about* the availability of the prospectus, and the core subject is a capital raise, CAP is the most specific fit. If the document were the prospectus itself, it might be classified differently, but as a short announcement confirming publication, CAP is appropriate, though RPA could also be considered if the focus was purely on the announcement mechanism. Given the explicit mention of the rights issue and directed issue (financing), CAP is superior to RPA or RNS.
2019-03-21 English
Resolutions at the Extraordinary General Meeting in BioInvent 2019
AGM Information Classification · 99% confidence The document is a press release dated March 20, 2019, detailing the resolutions passed at an Extraordinary General Meeting (EGM). The primary resolutions concern a rights issue (fundraising/capital structure change) and the authorization for an over-allotment option. While it discusses shareholder votes (EGM), the core subject is the capital raising activity. The document explicitly mentions the subscription price, record date, and subscription period for the new shares. This strongly aligns with the definition of 'Capital/Financing Update' (CAP). Although it relates to an EGM, the focus is the financial transaction (rights issue), not the voting results themselves (DVA) or general AGM materials (AGM-R). It is a direct announcement of a financing event.
2019-03-20 English
Beslut på BioInvents extra bolagsstämma 2019
Share Issue/Capital Change Classification · 99% confidence The document is a press release dated March 20, 2019, titled "Beslut på BioInvents extra bolagsstämma 2019" (Decisions at BioInvent's Extraordinary General Meeting 2019). The content details the approval of a rights issue (nyemission med företrädesrätt) and the authorization for the board to issue additional shares upon oversubscription. This relates directly to capital structure changes and financing activities. While it discusses decisions made at a general meeting, the primary focus is the capital raise mechanism (rights issue). This strongly aligns with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Audit Report (AR), or a simple Dividend Notice (DIV). It is an announcement about a significant financing event.
2019-03-20 Swedish
Notice to Annual General Meeting in BioInvent International AB
AGM Information Classification · 99% confidence The document is explicitly titled "Notice to Annual General Meeting in BioInvent International AB" and details the date, time, location, and procedures for shareholders to attend the AGM. Furthermore, the agenda items (1 through 17) cover standard AGM business, including the election of the Chairman, approval of the agenda, presentation of the Annual Report, resolutions on appropriations, election of the Board, and resolutions regarding remuneration guidelines and option programs. This content is the core material distributed to shareholders in advance of the meeting to inform their voting decisions, which aligns perfectly with the definition of materials shared during the Annual General Meeting (AGM-R). While it mentions the Annual Report (item 8a), the document itself is the notice and proposal document for the meeting, not the full 10-K or the standalone Audit Report.
2019-03-19 English
Kallelse till årsstämma i BioInvent International AB
AGM Information Classification · 99% confidence The document is titled "Kallelse till årsstämma i BioInvent International AB" (Notice of Annual General Meeting in BioInvent International AB). It details the date, time, location, and procedures for shareholders to attend and vote. The agenda explicitly lists items typical for an AGM, such as electing the chairman, approving the annual report (though the report itself is not the document), approving the disposition of profit, setting board fees, electing the board, and deciding on remuneration guidelines and an option program. This content is the formal notice and agenda for the Annual General Meeting. Based on the definitions: - 10-K is the full annual report, not the notice. - ER is an earnings release, not an AGM notice. - DEF 14A is remuneration information, which is only one part of this notice. - The document is clearly a notice calling shareholders to the AGM and outlining the proposals to be voted upon. The most appropriate classification is AGM-R (AGM Information), as it contains the formal call and the proposals to be discussed/voted on at the meeting.
2019-03-19 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.